Efficacy and Safety of Continuous Subcutaneous Insulin Infusion vs. Multiple Daily Injections on Type 1 Diabetes Children Aged ≤ 18 Years Old, a Meta-Analysis with Randomized Control Trials.

CONCLUSIONS: In conclusion, CSII is associated with lower HbA1C levels in children with type 1 diabetes but may have no effect on insulin requirement and reducing incidence of ketoacidosis and severe hypoglycemia. PMID: 30015622 [PubMed - as supplied by publisher]
Source: JCRPE Journal of Clinical Research in Pediatric Endocrinology - Category: Endocrinology Tags: J Clin Res Pediatr Endocrinol Source Type: research